Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men

HIV Medicine

Volumn 13, Issue 5, 2012, Pages 309-314

  Dolling, D ^a   Phillips, A N ^b   Delpech, V ^c   Pillay, D ^b   Cane, P A ^c   Crook, A M ^a   Shepherd, J ^d   Fearnhill, E ^a   Hill, T ^b   Dunn, D ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Drug resistance; HIV; Pre exposure prophylaxis

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MULTICENTER STUDY; PRIORITY JOURNAL; SEXUAL INTERCOURSE; UNITED KINGDOM;

ADENINE; ANTI-HIV AGENTS; COHORT STUDIES; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; LOGISTIC MODELS; MALE; PHOSPHONIC ACIDS; PREVALENCE; VIRAL LOAD;

EID: 84858178755     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00968.x     Document Type: Article

References (20)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA etal. on behalf of the CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174.
2. Grant RM, Lama JR, Anderson PL etal. for the iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-2599.
3. Van Rompay KK, Miller MD, Marthas ML etal. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000; 74: 1767-1774.
4. Metzner KJ, Binley JM, Gettie A, Marx P, Nixon DF, Connor RI. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques. Retrovirology 2006; 3: 97.
5. Cong M-E, Youngpairoj A, Zheng Q etal. Complete protection against rectal transmission of an emtricitabine-resistant SHIV162p3-M184V mutant by intermittent prophylaxis with Truvada. Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2011 [Abstract 31].
6. Paltiel AD, Freedberg KA, Scott CA etal. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes and cost-effectiveness. Clin Infect Dis 2009; 48: 806-815.
7. The UK Collaborative HIV Cohort (UK CHIC) Study Group. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5: 115-124.
8. Cane P, Chrystie I, Dunn D etal. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331: 1368-1371.
9. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42: 1608-1618.
10. Fox J, White PJ, Macdonald N etal. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med 2009; 10: 432-438.
11. Marks G, Crepaz N, Senterfitt W, Janssen R. Meta-analysis of high-risk sexual behaviour in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39: 446-453.
12. Quinn TC, Wawer MJ, Sewankambo N etal. for the Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-929.
13. Treating HIV-infected people with antiretrovirals protects partners from infection. Findings result from NIH-funded International Study HPTN 052. 2011. Available at (accessed 18 May 2011).
14. Bannister W, Cozzi-Lepri A, Kjær J etal. and the EuroSIDA Study Group. Prevalence of HIV-1 drug resistance mutations in patients on antiretroviral therapy in Europe. J Antimicrob Chemother 2011; 66: dkr006v1-dkdkr006.
15. Reekie J, Mocroft A, Ledergerber B etal. on behalf of EUROSIDA Study Group. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Med 2010; 11: 469-478.
16. Health Protection Agency. 2009. HIV in the UK: 2009 report.
17. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS etal. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011; 203: 1174-1181.
18. Van de Vjiver D, Derdelinckx I, Boucher C. Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of pre-exposure prophylaxis among young women in Zimbabwe. J Infect Dis 2009; 199: 1310-1317.
19. White KL, Margot NA, Wrin T etal. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46: 3437-3446.
20. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010; 39: 1048-1063.